The Genetics of Schizophrenia

Department of Genetics, Psychiatry, and Epidemiology, University of North Carolina, Chapel Hill, USA.
PLoS Medicine (Impact Factor: 14). 08/2005; 2(7):e212. DOI: 10.1371/journal.pmed.0020212
Source: PubMed

ABSTRACT Research into the etiology of schizophrenia, particularly the possible genetic basis, has never been as interesting and as provocative as in the past three years. Sullivan looks critically at the key research.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In the context of a stress-vulnerability framework, hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis is thought contribute to the risk, onset and course of psychotic illness. However, recent reports regarding static and dynamic features of the HPA axis suggest a more complex set of phenomena at play in the early phases of psychosis. We review literature regarding structural and functional aspects of the HPA axis in subjects at risk for or experiencing the first episode of psychosis, including evidence favoring as well as that which contradicts a model of HPA axis hyperactivation. Static measures of diurnal cortisol and hippocampal/pituitary volumes suggest that the HPA axis is in a hyperactivated state in early phases of psychosis. In contrast, the dynamic cortisol response to encountered or anticipated stress is blunted in the same populations. These incongruent findings need to be better understood. We consider potential explanations for the seemingly contradictory elevation and blunting of HPA biomarkers in the early course of psychosis. Finally, we propose and explore implications of a conceptual model of tonic HPA hyperactivation and phasic HPA blunting that integrates and reconciles these data. Copyright © 2015 Elsevier B.V. All rights reserved.
    Schizophrenia Research 01/2015; 162(1-3). DOI:10.1016/j.schres.2015.01.010 · 4.43 Impact Factor
  • Social Work in Mental Health 06/2014; 12(4):365-385. DOI:10.1080/15332985.2014.894487
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this chapter, we explore the basic science of the dopamine transporter (DAT), an integral component of a system that regulates dopamine homeostasis. Dopamine is a key neurotransmitter for several brain functions including locomotor control and reward systems. The transporter structure, function, mechanism of action, localization, and distribution, in addition to gene regulation, are discussed. Over many years, a wealth of information concerning the DAT has been accrued and has led to increased interest in the role of the DAT in a plethora of central nervous system diseases. These DAT characteristics are explored in relation to a range of neurological and neuropsychiatric diseases, with a particular focus on the genetics of the DAT. In addition, we discuss the pharmacology of the DAT and how this relates to disease and addiction. © 2015 Elsevier Inc. All rights reserved.
    Vitamins & Hormones 01/2015; 98:339-69. DOI:10.1016/bs.vh.2014.12.009 · 1.78 Impact Factor

Preview (2 Sources)

Available from